Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H81X | ISIN: SE0010573113 | Ticker-Symbol: 7ZA
Frankfurt
01.04.25
09:17 Uhr
0,237 Euro
-0,004
-1,46 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ASCELIA PHARMA AB Chart 1 Jahr
5-Tage-Chart
ASCELIA PHARMA AB 5-Tage-Chart

Aktuelle News zur ASCELIA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoThe Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025213NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE...
► Artikel lesen
18.03.Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025384MALMÖ, SE / ACCESS Newswire / March 18, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) , a biotech focused on improving the life of people living with rare cancer conditions, today announced...
► Artikel lesen
25.02.Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025122MALMÖ, SE / ACCESS Newswire / February 25, 2025 / Ascelia Pharma (STO:ACE) Today, on 25 February 2025, an extraordinary general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions...
► Artikel lesen
12.02.Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB256MALMO, SWEDEN / ACCESS Newswire / February 12, 2025 / Ascelia Pharma (STO:ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 7 May 2025 has been...
► Artikel lesen
07.02.Ascelia Pharma: Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study219MALMÖ, SWEDEN / ACCESS Newswire / February 7, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE) today published its Q4 and Full Year Report for 2024 (January - December), which...
► Artikel lesen
30.01.Notice of Extraordinary General Meeting in Ascelia Pharma AB271The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. MALMÖ, SE / ACCESS Newswire / January...
► Artikel lesen
27.01.Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting162MALMÖ, SE / ACCESSWIRE / January 27, 2025 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today...
► Artikel lesen
23.12.24Ascelia Pharma Patent Granted in China for Second Generation Orviglance491MALMÖ, SWEDEN / ACCESSWIRE / December 23, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions...
► Artikel lesen
ASCELIA PHARMA Aktie jetzt für 0€ handeln
17.12.24Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025290MALMO, SWEDEN / ACCESSWIRE / December 17, 2024 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two scientific abstracts...
► Artikel lesen
29.11.24Change in Number of Shares and Votes in Ascelia Pharma AB412MALMÖ, SE / ACCESSWIRE / November 29, 2024 / Ascelia Pharma (STO:ACE)During the month of November, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total of 26...
► Artikel lesen
22.11.24Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program390MALMÖ, SWEDEN / ACCESSWIRE / November 22, 2024 / Ascelia Pharma (STO:ACE) The board of directors of Ascelia Pharma AB ("Ascelia Pharma") has on 22 November 2024 resolved to convert 26,310 series C shares...
► Artikel lesen
07.11.24Ascelia Pharma AB: Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025187Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q3 for 2024 (January - September), which is now available on the company's website: https://www.ascelia.com/ir-media/financial-reports/KEY...
► Artikel lesen
15.08.24Ascelia Pharma AB: Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study132Ascelia Pharma AB (publ) (ticker: ACE) today published its Half-Year Report for 2024 (January - June), which is now available on the company's website: https://www.ascelia.com/ir-media/financial-reports/ KEY...
► Artikel lesen
14.08.24XFRA CAPITAL ADJUSTMENT INFORMATION - 14.08.2024862Das Instrument 31V KYG9361V1086 VINDA INTL HLDGS HD-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 14.08.2024 und ex Kapitalmassnahme am 15.08.2024 The instrument 31V KYG9361V1086 VINDA INTL HLDGS...
► Artikel lesen
09.08.24Ascelia Pharma AB: Ascelia Pharma Announces Final Terms of Rights Issue180NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE...
► Artikel lesen
16.05.24Ascelia Pharma AB: Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study563Ascelia Pharma AB (publ) (ticker: ACE) today published its Interim Report Q1 for 2024 (January - March), which is now available on the company's website though this link.KEY EVENTS IN Q1 2024Nomination...
► Artikel lesen
02.05.24Ascelia Pharma AB: Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study225Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1